23.09.2014 - Reneuron Group, a leading UK-based stem cell therapy company, has appointed Olav Hellebø as their new Chief Executive Officer.
A highly experienced pharmaceutical executive, Hellebø has broad commercial experience gained at both major pharmaceutical and small biotechnology companies in the fields of clinical development, commercialism and marketing of new therapeutics. Before taking on the role of CEO at ReNeuron, Hellebø held the position of CEO at Clavis Pharma ASA, a Norwegian company specialising in oncology. Prior to Clavis, Hellebø was at the helm of UCB Pharma and head of the UK operations of Novartis. Hellebø began his pharmaceutical career in 1992 at Schering-Plough, where he held senior commercial roles in Europe and the US.http://www.european-biotechnology-news.com/people/bio-people/2014/olav-hellebo.html